Imbalanced expression of dysfunctional regulatory T cells and T-helper cells relates to immunopathogenesis in polyarteritis nodosa

Modern Rheumatology

Volumn 27, Issue 1, 2017, Pages 102-109

  Shimojima, Yasuhiro ^a   Ishii, Wataru ^a   Kishida, Dai ^a   Fukushima, Kazuhiro ^a   Ikeda, Shu Ichi ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CTLA 4; Polyarteritis nodosa; Regulatory T cells; T helper cells

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 4; MYELOBLASTIN; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE; CTLA4 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; ASSESSMENT OF HUMANS; BIRMINGHAM VASCULITIS ACTIVITY SCORE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GRANULOMATOSIS; HELPER CELL; HUMAN; HUMAN CELL; IMMUNOPATHOGENESIS; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; POLYARTERITIS NODOSA; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TH1 CELL; TH17 CELL; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; CTLA-4 ANTIGEN; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; POLYARTERITIS NODOSA; T-LYMPHOCYTES, HELPER-INDUCER; T-LYMPHOCYTES, REGULATORY;

EID: 84965063687     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2016.1172999     Document Type: Article

References (45)

1. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013;65:1–11.
2. Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis. 2007;66:222–7.
3. Jennette JC, Falk RJ., Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease. Nat Rev Rheumatol. 2014;10:463–73.
4. Hernandez-Rodriguez J, Alba MA, Prieto-Gonzalez S, Cid MC., Diagnosis and classification of polyarteritis nodosa. J Autoimmun. 2014;48–49:84–9.
5. Cid MC, Grau JM, Casademont J, Campo E, Coll-Vinent B, Lopez-Soto A, et al. Immunohistochemical characterization of inflammatory cells and immunologic activation markers in muscle and nerve biopsy specimens from patients with systemic polyarteritis nodosa. Arthritis Rheum. 1994;37:1055–61.
6. O'Shea JJ, Paul WE., Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells. Science. 2010;327:1098–102.
7. Bettelli E, Korn T, Oukka M, Kuchroo VK., Induction and effector functions of T(H)17 cells. Nature. 2008;453:1051–7.
8. Schmidt A, Oberle N, Krammer PH., Molecular mechanisms of treg-mediated T cell suppression. Front Immunol. 2012;3:51. DOI:10.3389/fimmu.2012.00051.
9. Zheng SG., Regulatory T cells vs Th17:differentiation of Th17 versus Treg, are the mutually exclusive? Am J Clin Exp Immunol. 2013;2:94–106.
10. Schneider A, Rieck M, Sanda S, Pihoker C, Greenbaum C, Buckner JH., The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells. J Immunol. 2008;181:7350–5.
11. Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, et al. Modification and validation of the Birmingham vasculitis activity score (version 3). Ann Rheum Dis. 2009;68:1827–32.
12. Dige A, Hvas CL, Kelsen J, Deleuran B, Dahlerup JF, Agnholt J., Ethylene-Diamine-tetra-acetate (EDTA) mimics the effect of regulatory T cells in suppression assays:a potential pitfall when using AutoMACS-separated cells. J Immunol Methods. 2010;353:141–4.
13. Sakaguchi S, Ono M, Setoguchi R, Yagi H, Hori S, Fehervari Z, et al. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev. 2006;212:8–27.
14. Abdulahad WH, Stegeman CA, van der Geld YM, Doornbos-van der Meer B, Limburg PC, Kallenberg CG., Functional defect of circulating regulatory CD4+ T cells in patients with Wegener's granulomatosis in remission. Arthritis Rheum. 2007;56:2080–91.
15. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med. 2006;203:1701–11.
16. Saadoun D, Garrido M, Comarmond C, Desbois AC, Domont F, Savey L, et al. Th1 and Th17 cytokines drive inflammation in Takayasu arteritis. Arthritis Rheumatol. 2015;67:1353–60.
17. Deng J, Younge BR, Olshen RA, Goronzy JJ, Weyand CM., Th17 and Th1 T-cell responses in giant cell arteritis. Circulation. 2010;121:906–15.
18. Abdulahad WH, Stegeman CA, Limburg PC, Kallenberg CG., Skewed distribution of Th17 lymphocytes in patients with Wegener's granulomatosis in remission. Arthritis Rheum. 2008;58:2196–205.
19. Abdulahad WH, Lamprecht P, Kallenberg CG., T-helper cells as new players in ANCA-associated vasculitides. Arthritis Res Ther. 2011;13:236.
20. Free ME, Bunch DO, McGregor JA, Jones BE, Berg EA, Hogan SL, et al. Patients with antineutrophil cytoplasmic antibody-associated vasculitis have defective Treg cell function exacerbated by the presence of a suppression-resistant effector cell population. Arthritis Rheum. 2013;65:1922–33.
21. Murphy AC, Lalor SJ, Lynch MA, Mills KH., Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis. Brain Behav Immun. 2010;24:641–51.
22. Hsu HC, Yang P, Wang J, Wu Q, Myers R, Chen J, et al. Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat Immunol. 2008;9:166–75.
23. Weyand CM, Goronzy JJ., Immune mechanisms in medium and large-vessel vasculitis. Nat Rev Rheumatol. 2013;9:731–40.
24. Muller A, Trabandt A, Gloeckner-Hofmann K, Seitzer U, Csernok E, Schonermarck U, et al. Localized Wegener's granulomatosis:predominance of CD26 and IFN-gamma expression. J Pathol. 2000;192:113–20.
25. Lamprecht P, Bruhl H, Erdmann A, Holl-Ulrich K, Csernok E, Seitzer U, et al. Differences in CCR5 expression on peripheral blood CD4 + CD28- T-cells and in granulomatous lesions between localized and generalized Wegener's granulomatosis. Clin Immunol. 2003;108:1–7.
26. Tang Q, Boden EK, Henriksen KJ, Bour-Jordan H, Bi M, Bluestone JA., Distinct roles of CTLA-4 and TGF-beta in CD4 + CD25+ regulatory T cell function. Eur J Immunol. 2004;34:2996–3005.
27. Jury EC, Flores-Borja F, Kalsi HS, Lazarus M, Isenberg DA, Mauri C, et al. Abnormal CTLA-4 function in T cells from patients with systemic lupus erythematosus. Eur J Immunol. 2010;40:569–78.
28. Flores-Borja F, Jury EC, Mauri C, Ehrenstein MR., Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis. Proc Natl Acad Sci USA. 2008;105:19396–401.
29. Chikuma S, Imboden JB, Bluestone JA., Negative regulation of T cell receptor-lipid raft interaction by cytotoxic T lymphocyte-associated antigen 4. J Exp Med. 2003;197:129–35.
30. Morgan MD, Day CJ, Piper KP, Khan N, Harper L, Moss PA, et al. Patients with Wegener's granulomatosis demonstrate a relative deficiency and functional impairment of T-regulatory cells. Immunology. 2010;130:64–73.
31. Tian L, Humblet-Baron S, Liston A., Immune tolerance:are regulatory T cell subsets needed to explain suppression of autoimmunity? Bioessays. 2012;34:569–75.
32. Ichiyama K, Yoshida H, Wakabayashi Y, Chinen T, Saeki K, Nakaya M, et al. Foxp3 inhibits RORgammat-mediated IL-17A mRNA transcription through direct interaction with RORgammat. J Biol Chem. 2008;283:17003–8.
33. Zhou L, Lopes JE, Chong MM, Ivanov, II, Min R, Victora GD, et al. TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature. 2008;453:236–40.
34. Lopes JE, Torgerson TR, Schubert LA, Anover SD, Ocheltree EL, Ochs HD, et al. Analysis of FOXP3 reveals multiple domains required for its function as a transcriptional repressor. J Immunol. 2006;177:3133–42.
35. Lord JD, Valliant-Saunders K, Hahn H, Thirlby RC, Ziegler SF., Paradoxically increased FOXP3+ T cells in IBD do not preferentially express the isoform of FOXP3 lacking exon 2. Dig Dis Sci. 2012;57:2846–55.
36. Zheng Y, Chaudhry A, Kas A, deRoos P, Kim JM, Chu TT, et al. Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control T(H)2 responses. Nature. 2009;458:351–6.
37. Wan YY, Flavell RA., Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression. Nature. 2007;445:766–70.
38. Pesenacker AM, Bending D, Ursu S, Wu Q, Nistala K, Wedderburn LR., CD161 defines the subset of FoxP3+ T cells capable of producing proinflammatory cytokines. Blood. 2013;121:2647–58.
39. Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A, et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity. 2009;30:899–911.
40. Sakaguchi S., Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol. 2004;22:531–62.
41. Ayyoub M, Deknuydt F, Raimbaud I, Dousset C, Leveque L, Bioley G, et al. Human memory FOXP3+ Tregs secrete IL-17 ex vivo and constitutively express the T(H)17 lineage-specific transcription factor RORgammat. Proc Natl Acad Sci USA. 2009;106:863540.
42. Lee YK, Mukasa R, Hatton RD, Weaver CT., Developmental plasticity of Th17 and Treg cells. Curr Opin Immunol. 2009;21:274–80.
43. Voo KS, Wang YH, Santori FR, Boggiano C, Wang YH, Arima K, et al. Identification of IL-17-producing FOXP3+ regulatory T cells in humans. Proc Natl Acad Sci USA. 2009;106:4793–8.
44. Pagnoux C, Seror R, Henegar C, Mahr A, Cohen P, Le Guern V, et al. Clinical features and outcomes in 348 patients with polyarteritis nodosa:a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French vasculitis study group database. Arthritis Rheum. 2010;62:616–26.
45. Ribi C, Cohen P, Pagnoux C, Mahr A, Arene JP, Puechal X, et al. Treatment of polyarteritis nodosa and microscopic polyangiitis without poor-prognosis factors:a prospective randomized study of one hundred twenty-four patients. Arthritis Rheum. 2010;62:1186–97.